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HIV-1 has dual co-receptor tropism, i.e., following interaction with
the CD4 molecule, different isolates efﬁciently bind to CCR5 and/or
CXCR4 for entry to different types of target cells (Glushakova et al.,
1999; Granelli-Piperno et al., 1996; Scarlatti et al., 1997). HIV-1
isolates recovered early during acute infection are overwhelmingly
R5-tropic while isolates recovered during late chronic phases can be
X4-tropic, with a preserved ability to use CCR5 (Scarlatti et al., 1997).
In addition to CCR5 and/or CXCR4, other chemokine and chemokine-
like orphan receptors have been shown to be utilized by HIV as co-
receptors for entry into different target cells with varying degrees of
efﬁciency (Albright et al., 1999; Glushakova et al., 1999; Granelli-
Piperno et al., 1996; Pohlmann et al., 1999a; Scarlatti et al., 1997; Xiao
et al., 1998). In contrast to HIV, most SIV strains have been reported to
be predominantly R5-tropic with very few variants shown to be X4-
tropic (DeGottardi et al., 2008; Del Prete et al., 2009; Lauren et al.,
2006; Means et al., 2001; Picker et al., 2004). The pathogenic
SIVmac239 virus, a prototypic strain used for many studies, has been
shown to bemainly R5-tropic (Edinger et al., 1998; Lauren et al., 2006;
Pohlmann et al., 2000, 1999b; Sharron et al., 2000). However, cell-to-
cell fusion assays and different entry assays using transformed cell
lines found that chemokine receptor-like orphan receptors such as
CXCR6 (STRL33/Bonzo) and GPR15 (BOB) might also be used, albeitless efﬁciently (Edinger et al., 1998; Lauren et al., 2006; Pohlmann
et al., 2000, 1999b; Sharron et al., 2000).
A 32-base pair deletion (Δ32) in the human CCR5 gene resulting in
loss of or signiﬁcantly diminished expression of CCR5 (Blanpain et al.,
2000; Connor et al., 1996; Liu et al., 1996;Mulherin et al., 2003; Paxton
et al., 1996; Rana et al., 1997) has been associated with resistance to
infection with R5-tropic HIV-1 strains (Hoffman et al., 1997; Huang
et al., 1996; Oh et al., 2008; Zimmerman et al., 1997). Similar to the
human Δ32 CCR5 gene mutation, a 24-base pair deletion (Δ24) in the
CCR5 gene has been reported in some red-capped mangabeys (RCM),
conferring resistance to R5-tropic SIV viruses (Chen et al., 1998).
Therefore,Δ24 homozygote RCMderived PBMC are permissive only to
the CCR2b-tropic SIVrcm strain (Chen et al., 1998). On the other hand,
analyses of polymorphisms in the CCR5 gene from SIV-infected rhesus
macaques did not ﬁnd any associations between polymorphisms in
CCR5 and control of virus replication (Weiler et al., 2006). Thus, the
role of CCR5 expression levels in determining susceptibility of rhesus
macaque CD4+ T-cells to SIV infection is not clearly deﬁned.
Studies comparing HIV/SIV infection of CCR5-expressing and non-
expressing cells suggest that high levels of cell surface CCR5 are
required for efﬁcient target cell infection (DeGottardi et al., 2008;
Glushakova et al., 1999; Granelli-Piperno et al., 1996; Lin et al., 2002;
Means et al., 2001; Picker et al., 2004; Scarlatti et al., 1997). However,
these studies typically assessed CCR5 expression at a single time point
and assumed that the levels of surface expression remain constant
over resting and activated cell states. Because HIV-1 infection and
replication is more efﬁcient in actively dividing cells (Vatakis et al.,
2007, 2009), most in vitro protocols for SIV infection of rhesus
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or CD3 monoclonal antibody (mAb), 24–48 h prior to infection
(Minang et al., 2009; Sacha andWatkins, 2010).We recently observed
that primary rhesus macaque PBMC-derived CD4+ T-cell clones
expressing similar levels of surface CD4, show clonal differences in
susceptibility to infection with SIVmac239. We therefore asked
whether differential levels of expression of CCR5 might account for
the clonal differences in susceptibility to SIV. We found that clonal
differences in susceptibility to infection of rhesus macaque CD4+ T-
cells by SIVmac239 is independent of levels of CCR5 surface expression.
Results
Dynamics of surface CCR5 expression by primary rhesus macaque CD4+
T-cell clones
Infection of 9 CD4+ T-cell clones from 3 rhesus macaques 24 h
after plate-bound CD3 mAb stimulation revealed considerable clonal
differences in their susceptibility to infection and kinetics of
replication of SIVmac239 as measured by anti-p27 staining 5 days PI
(Fig. 1 and data not shown). Of the nine clones presented, three were
highly infectable (H; SIV Gag p27+ cells ≥30%), ﬁve were poor hosts
for SIV (i.e. low-to-resistant, L/R; SIV Gag p27+ cells b10%), and one
had an intermediate number of infected cells (I; SIV Gag p27+ cells
≥10% but b30%). This relative difference in SIV susceptibility between
clones was consistent in multiple infection experiments using
additional clones from eight rhesus macaques (Supplemental
Table 1). The clones were stimulated on the same schedule and
expressed high and comparable levels of surface CD4 at the time of
infection (Supplemental Fig. 1; data not shown), suggesting that these
parameters or genetic differences between animals were not the
cause of the observed variability. All clones were of effector memory
phenotype (CD28−, CD95+) after in vitro culture (data not shown).Fig. 1. Primary rhesus macaque CD4+ T-cells show clonal differences in susceptibility to infe
were stimulated with plate-bound CD3 mAb. Twenty-four hours later, the cells were infected
SIV Gag p27+ cells was determined by intracellular staining and ﬂow cytometry on day 5 PIn light of reports suggesting that virus-speciﬁc effector memory
CD4+ T-cells may be more susceptible to HIV/SIV infection (Douek
et al., 2002; Okoye et al., 2009), and because some of the CD4+ T-cell
clones used in this study were generated from SIV DNA vaccinated
macaques, we evaluated all the clones from vaccinated animals for
reactivity to SIVmac239 Gag, Pol and Acc peptide pools (SIV Env was
not included in the vaccine construct). Three CD4+ T-cell clones
(C0102-17, -21 and -55) out of 26 tested clones were found to be SIV
Gag reactive (Supplemental Fig. 2; IFN-γ responses by a representa-
tive SIV Gag-speciﬁc CD4+ T-cell clone). All three clones showed low
or intermediate susceptibility to infection compared with the non-SIV
reactive clones (Supplemental Table 1).
To test if CCR5 expression levels could account for the differences
in SIV susceptibility, we measured surface expression of CCR5 on
resting CD4+ T-cell clones and 24–48 h after activation. Using PE-
conjugated mouse IgG1 k as isotype control mAb to establish back-
ground CCR5 staining, 88–100% and 2–15% of the clonal population of
CD4+ T-cells at resting and after activation, respectively, were
positive for CCR5 expression (Fig. 2A; data for 2 representative clones
from 2 animals; and data not shown). When the GMFI of CCR5
expression was analyzed for 21 clones from 5 animals, resting CD4+
T-cell clones showed high but considerably variable levels of surface
CCR5 (Fig. 2B). Surface CCR5 expression was signiﬁcantly down-
regulated (up to 50-fold reduction for one clone) 24–48 h post
stimulation, and partially recovered 1 week after, being signiﬁcantly
higher than the 24–48 h post stimulation levels (Fig. 2B; pb0.0005).
Stimulation of CD4+ T-cell clones with phytohemagglutinin (PHA),
soluble CD3 mAb or a cocktail of soluble CD3 and CD28 mAbs, yielded
similar CCR5 downregulation (data not shown).
To examine the kinetics of recovery in ﬁner detail, surface CCR5
levels on 8 clones from 3 animals were measured 24 h after CD3 mAb
stimulation, and every second day until day 13. Only a representative
subset of the original 29 CD4+ T-cell clones were included in thesection with SIVmac239. Nine CD4+ T-cell clones from three uninfected rhesus macaques
with cell-free SIVmac239 for 3 h, washed and plated in 24-well plates. The frequency of
I.
Fig. 2. CCR5 is differentially expressed at high levels in resting primary rhesus macaque CD4+ T-cells but uniformly downregulated in response to T-cell receptor triggering.
A) Percentage of CCR5 positive cells in CD4+ T-cell clones from two monkeys at resting and 24 h after CD3 stimulation compared to isotype control background staining. B) CCR5
expression by 21 CD4+ T-cell clones from 5 rhesus macaques analyzed at resting, 24–48 h and 1 week after CD3 mAb stimulation. Box plots show geometric mean ﬂuorescent
intensities (GMFI) of surface CCR5 expression determined by ﬂow cytometry with the median, 95 percentile and maximum values indicated for each group. C) Surface CCR5
expression dynamics by 8 CD4+ T-cell clones from 3 rhesusmacaques analyzed by ﬂow cytometry every second day until day 13 following stimulation. D) CCR5mRNA expression by
4 CD4+ T-cell clones from 2 rhesus macaques was determined by qPCR 24–48 h and 1 week after stimulation. Shown are means and standard deviations of CCR5 mRNA copies per
106 CCR5 DNA copies. The paired Students t test was used in analyses for B and D with signiﬁcance set at a p value≤0.05 where ****=pb0.00005, ***=pb0.0005, **=pb0.005 and
*=pb0.05.
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clones in continuous culture for the total time of the study. Overall,
CCR5 expression was downregulated 24 h post stimulation with a
gradual return over the next 7 days, reaching pre-stimulation levels
between days 7 and 10 post stimulation (Fig. 2C). Similar results were
seen when CCR5 expression was measured on freshly isolated PBMC
from two monkeys, excluding the possibility that the dynamic CCR5
expression on CD4+ T-cell clones was a result of long-term in vitro
culture (Supplemental Fig. 3). Studies in human cells found that
surface CCR5 downregulation after activation is in part due to
decreased CCR5 mRNA expression (Carroll et al., 1997). When levels
of CCR5 mRNA expression in 4 clones from 2 animals were analyzed
and normalized to number of cells (CCR5 DNA copies), we observed a
5–17 fold reduction in CCR5 mRNA copies for the cells analyzed 24–
48 h compared to 1 week after stimulation (Fig. 2D; p=0.02). These
data suggest that part of the activation-induced CCR5 downregulation
on rhesus CD4+ T-cells occurs at the transcriptional level, similar to
the case in human T-cells.
Levels of SIV Gag p27-expression or cell-associated viral DNA in
SIV-infected macaque CD4+ T-cells are not related to the levels of
surface CCR5 at time of infection
We next asked whether SIVmac239 infection and replication in
macaque CD4+ T-cells is affected by the levels of surface CCR5 at time
of infection. We infected 21 CD4+ T-cell clones from 5 rhesusmacaques 24–48 h (CCR5low) and 1 week (CCR5high) after CD3 mAb
stimulation with cell-free SIVmac239, and assessed the levels of
intracellular SIV Gag p27 expression on day 5 PI by ﬂow cytometry.
The levels of surface CD4 and CCR5 on the day of infection as well as at
the time of harvest were also determined.
We observed a wide variation in the levels of intracellular SIV Gag
p27 expression between the clones on day 5 PI. However, there was
no signiﬁcant difference in the median GMFI of SIV Gag p27 staining
between matched cells infected at 24–48 h (CCR5low) and 1 week
(CCR5high) post stimulation (Fig. 3A). Correlation analyses of the
intensity of SIV Gag p27 staining on day 5 PI and the levels of surface
CCR5 expression at the time of infection did not show a direct
relationship between these parameters (Fig. 3B, r=−0.27). Produc-
tive infection did not signiﬁcantly affect CCR5 expression: surface
CCR5 levels were similar in the SIV Gag p27+ and SIV Gag p27−
fractions of cells from the same clonal population on day 5 PI (Fig. 3C).
As expected for SIV infection, surface CD4 levels were signiﬁcantly
downregulated in the SIV Gag p27+ cell fraction of cultures of
SIVmac239-infected cells (Fig. 3D; pb0.0005).
Because of the dynamic pattern of CCR5 expression during the
5 days incubation between infection and SIV Gag p27 analyses, we
next investigated whether levels of cell-associated viral DNA
measured early after infection could be related to the levels of surface
CCR5 at the time of infection. To address this, we infected 4 CD4+ T-
cell clones from 2 rhesusmacaqueswith SIVmac239 24–48 h (CCR5low)
and 1 week (CCR5high) after CD3 mAb stimulation. As indicated
Fig. 3. CCR5 expression levels by primary rhesus macaque CD4+ T-cells at time of infection with SIVmac239 do not correlate with the levels of SIV Gag p27 expression. Rhesus
macaque CD4+ T-cell clones were infectedwith cell-free SIVmac239 either 24–48 h or 1 week after -CD3mAb stimulation. A) Geometric mean ﬂuorescent intensity (GMFI) of SIV Gag
p27 expression on day 5 PI. B) Correlation plot of GMFI of SIV Gag p27 staining on day 5 PI and surface CCR5 expression at time of infection. C) GMFI of surface CCR5 and D) CD4
expression by SIV Gag p27 negative and positive cell fractions on day 5 PI. All plots show data for 21 CD4+ T-cell clones from 5 rhesus macaques. Stained cell acquisition and analyses
was by ﬂow cytometry. Group comparisons were by the paired Students t test and correlation analyses by the Spear man rank order correlation with signiﬁcance set at a
p value≤0.05 where ***=pb0.0005.
Fig. 4. Copies of cell-associated viral DNA early (1–4 days PI) during viral replication are
not related to levels of surface expression of CCR5 at time of infection. Four CD4+ T-cell
clones from 2 rhesus macaques were infected 24–48 h and 1 week after CD3 mAb
stimulation with cell-free DNase-treated SIVmac239, and levels of cell-associated viral
DNA determined 9, 24, 48 and 96 h PI by QPCR.
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clones that were intermediate-to-highly infectable were used in this
set of experiments because of the technical difﬁculty of maintaining
all the clones long-term for the duration of the study. Cell-associated
viral DNA was analyzed from aliquots of cell suspensions harvested 9,
24, 48 and 96 h PI by QPCR. Using our infection protocol, typically less
than 1% of the cells are SIV Gag p27+ before 3 days post infection
when analyzed by ﬂow cytometry (Minang et al., 2008). Although the
levels of cell-associated viral DNA varied between individual clones,
the levels expressed by the same clones infected 24–48 h (CCR5low)
and 1 week (CCR5high) post stimulation were similar at all tested time
points PI (Fig. 4). Hence, the levels of surface CCR5 expression by
macaque CD4+ T-cells at the time of virus exposure had no
measurable impact on the infection efﬁciency at early time points.
Reduction of CCR5 by RNAi has no effect on SIVmac239 infection of
macaque CD4+ T-cells
It was possible that the observed recovery in CCR5 expression
following CD3 mAb stimulation allowed for increased spread of the
virus over time. To exclude this possibility, one of the CD4+ T-cell
clones that showed intermediate susceptibility to SIV infection was
transduced with a macaque CCR5 shRNA retroviral vector and two
independent subclones were isolated by sorting for the GFP marker
carried in the shRNA vector. The CCR5 shRNA transduced CD4+ T-cell
subclones showed stable and markedly downregulated expression of
CCR5 compared to the untransduced parental clone without affectingother surface markers such as CD4 (Fig. 5A and data not shown). CCR5
shRNA transduced CD4+ T-cell subclones and the untransduced
parental clone were infected 1 week after CD3 mAb stimulation with
SIVmac239. The frequency of SIV Gag p27-expressing cells was
determined by intracellular staining and ﬂow cytometry. Cultures of
the CCR5 shRNA transduced (CCR5low) and parental untransduced
(CCR5high) CD4+ T-cells showed similar frequencies of SIV Gag p27+
Fig. 5. CCR5 RNAi-mediated inhibition of CCR5 expression has no impact on the
susceptibility of macaque CD4+ T-cells to SIVmac239. A) A rhesus macaque CD4+ T-cell
clone (DBN2-9) was transduced with CCR5 shRNA using a retroviral vector construct
that included the gene encoding green ﬂuorescent protein (GFP) as a reporter. Surface
CCR5 expression by the transduced and parental cells was determined by ﬂow
cytometry. B) CCR5 shRNA transduced and untransduced clones were infected with
SIVmac239 1 week after CD3mAb stimulation, and SIV Gag p27 expression was assessed
on day 12 PI by ﬂow cytometry.
136 J.T. Minang et al. / Virology 409 (2011) 132–140cells 12 days after infection (Fig. 5B). Thus, CCR5 shRNA-mediated
knockdown of CCR5 expression had no measurable impact on the
level of SIVmac239 infection and replication efﬁciency as assessed by
SIV Gag p27 expression.
A CCR5 antagonist blocks SIVmac239 infection of macaque CD4
+ T-cells
at CCR5low- and CCR5high-expressing states to comparable degrees
Because we found that RNAi-mediated CCR5 downregulation does
not impact SIVmac239 infection of macaque CD4+ T-cells, we hypoth-
esized that very low levels of CCR5 expression may be sufﬁcient for
SIVmac239 infection of macaque CD4+ T-cells. To test this, 8 CD4+ T-cell
clones with intermediate-to-high susceptibility to SIVmac239 infection
from 5 rhesus macaques were pretreated with 10 μM of the CCR5
antagonist maraviroc at CCR5low (24–48 after stimulation) and CCR5high
(resting) expression states before infection with SIVmac239. The
frequency of SIV Gag p27-expressing cells was determined by
intracellular staining and ﬂow cytometry on day 4 and 7 PI. Pretreat-
ment with maraviroc resulted in a marked reduction in the frequency
of SIV Gag p27-expressing cells both in culture of cells infected at
CCR5low- and CCR5high-expression states (Fig. 6A; data for 4 represen-
tative clones on day 7 PI). When the data for cultures with drug were
normalized for all 8 tested clones, the differences were found to be
signiﬁcant at both time points (Fig. 6B). Noteworthy, the blocking effect
of the drug for cells infected at CCR5low- and CCR5high-expression states
was similar. Similar results were obtained when SIV Gag p28 levels in
culture supernatants were determined by Enzyme-linked immunosor-
bent assay (data not shown). Ourdata suggests that a very low threshold
level of surface CCR5 expression is necessary for efﬁcient SIVmac239
infection of macaque CD4+ T-cells, but that wide differences in CCR5
expression above this threshold do not affect susceptibility to infection.
We next investigated whether other reportedminor SIVmac239 co-
receptors (Sharron et al., 2000; Unutmaz et al., 2000) are regulatedsimilar to CCR5 in primary macaque CD4+ T-cells. We analyzed
expression of the chemokine-like orphan receptors CXCR6 (STRL33/
Bonzo) and GPR15 (BOB) on 2 CD4+ T-cell clones (one that showed
high and the other intermediate susceptibility to SIV infection) from 2
different animals 24–48 h and 1 week after CD3 mAb stimulation.
CXCR6 expression ranged from stable-to-slightly upregulated 24–
48 h after stimulation (Fig. 7A), whereas GPR15 levels were generally
low-to-undetectable and were unaffected by stimulation (data not
shown). This suggests that surface expression of CCR5 and CXCR6 is
differentially regulated, but the direct role of CXCR6 on SIV infection
could not be tested due to lack of CXCR6-speciﬁc neutralizing mAb
(Sharron et al., 2000).
Discussion
In this study we report substantial clonal differences in suscepti-
bility of rhesus macaque CD4+ T-cells to SIV infection. We de-
monstrate that surface CCR5 levels vary considerably on different
resting macaque CD4+ T-cell clones and that T-cell receptor (TCR)
triggering results in dramatic downregulation of CCR5 expression.We
also show that the level of surface CCR5 expression at time of infection
is not related to susceptibility to SIVmac239. Finally, we show that
CCR5 downregulation involves an RNA mechanism, similar to the
prior results in human cells (Carroll et al., 1997). Together, our
ﬁndings suggest that CCR5 density above a low threshold is not a
factor determining susceptibility of macaque CD4+ T-cells to SIV
infection.
Because most infection protocols for SIV suggest infection after
stimulation of the target cells (Minang et al., 2009; Sacha and
Watkins, 2010), our observation that surface CCR5 expression was
markedly downregulated following CD3 mAb stimulation was
intriguing. The dynamic changes in CCR5 expression have important
implications for in vivo studies suggesting selective infection and
depletion of CD4+CCR5+ T-cells. Veazey et al. (2000) reported that
CD4+CCR5+ T-cells are selectively depleted in the gut during acute
SIV infection of rhesus macaques. While the bulk of the CD4+ T-cell
loss is due to infection, it is possible that the lower frequencies of CD4
+CCR5+ T-cells in the gut compared with CD4+CCR5low/− cells after
SIV infection is partly due to downregulation of CCR5, as CD4+ T-cells
become activated from the generalized inﬂammatory environment
known to occur in this tissue during acute infection (Campillo-
Gimenez et al., 2009; Meythaler et al., 2009). Therefore, the skewed
levels of CD4+CCR5low/− T-cells might be due to activation-induced
CCR5 downregulation rather than a virus resistant CD4+CCR5low/− T-
cell pool. Furthermore, IL-15 treatment during acute SIV infection of
rhesus macaques was shown to result in a dramatic decrease in the
frequency of CD4+CCR5+ T-cells despite a demonstrated increase
in the frequency of Ki-67+CD4+ (activated/proliferating) T-cells
(Mueller et al., 2008). However, it is possible that the Ki-67+CD4+
cells may have downregulated CCR5 expression consistent with our
in vitro data with CD3 mAb stimulated CD4+ T-cells. Pandrea et al.
(2007) showed that uninfected natural SIV host species express lower
levels of CCR5 compared to rhesus macaques. However, similar levels
of acute viral load are seen in natural hosts and rhesus macaques (Lay
et al., 2009; Mattapallil et al., 2005). This together with data from
Mattapallil et al. (2005) is consistent with ourmodel that low levels of
CCR5 expression are sufﬁcient for efﬁcient infection. Whereas total
CD4+ T-cell loss has been reported in gut biopsies and PBMC from
sooty mangabeys (natural hosts) acutely infected with SIV at levels
comparable with acutely infected rhesus macaques (Lay et al., 2009;
Mattapallil et al., 2005), CD4+CCR5+ T-cell loss is more pronounced in
rhesus macaques (Monceaux et al., 2007). This is consistent with the
elevated immune activation observed in SIV-infected macaques.
Because it is complex to control for time or duration of activation
during in vivo studies, it is difﬁcult to distinguish between cells that
were consistently CCR5low/−, and those that were CCR5high but
Fig. 6. Pretreatment of macaque CD4+ T-cells with the CCR5 antagonist maraviroc (MRC) before infection with SIVmac239 blocks infection of cells exposed to virus at CCR5low and
CCR5high expression states to a comparable degree. A) CD4+ T-cell clones from four rhesus macaques were infected with SIVmac239 in the absence or presence of the 10 μM CCR5
antagonist, and the frequency of SIV Gag p27 positive cells determined on day 7 PI by ﬂow cytometry. B) Frequency of SIV Gag p27 positive cells shown as mean and standard
deviation on day 4 and 7 PI for eight CD4+ T-cell clones from ﬁve rhesus macaques infected in the absence (grey) or presence (black) of maraviroc at CCR5low or CCR5high expression
states. The data were normalized for frequency of SIV Gag p27 positive cells in cultures of infected cells without drug.
137J.T. Minang et al. / Virology 409 (2011) 132–140subsequently downregulated CCR5 upon activation. Our results
suggest that caution be applied in interpreting CCR5 data from in
vivo studies.Fig. 7. CXCR6 (Bonzo/STRL33) surface expression by primary rhesus macaque CD4+ T-cell cl
expression by 2 CD4+ T-cell clones from 2 rhesus macaques analyzed 24–48 h (black) andLevine et al., showed that TCR triggering using CD3 mAb stimula-
tion together with CD28 co-stimulation rendered CD4+ T-cells from
HIV-1 infected and uninfected donors highly resistant to infection byones are stable-to-slightly upregulated in response to T-cell receptor triggering. CXCR6
1 week (grey) after CD3 mAb stimulation by ﬂow cytometry.
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demonstrated that their resistance to HIV-1 infection correlated with
the absence of detectable CCR5mRNA expression (Carroll et al., 1997).
Our data extends this ﬁnding of activation-induced transcriptional
control of CCR5 to the rhesus model. However, unlike HIV-1 infection
of human PBMC or T-cell lines shown to correlate with cell surface
CCR5 density in vitro (Lin et al., 2002; Salkowitz et al., 2003), we show
that reduced levels of CCR5 expression by macaque CD4+ T-cells after
activation has no measurable impact on the efﬁciency of SIVmac239
infection. In line with this, Mattapallil et al. (2005) showed that the
level of viral infection, as measured by SIV Gag DNA, was essentially
the same in sorted CD4+ CCR5+ and CD4+ CCR5− cells obtained from
different tissues of rhesus macaques acutely infected with SIVmac239.
We did not ﬁnd any difference in susceptibility to infection between
macaque CD4+ T-cells that were CCR5low (following activation or
RNAi transduction) and those that were CCR5high (resting) at the time
of infection, and pretreatment of cells with saturating amounts of a
CCR5 antagonist signiﬁcantly reduced infection of both cell popula-
tions. Noteworthy, pretreatment of CD4+ T-cell clones that showed
the highest susceptibility to SIVmac239 infection (typically ≥80% SIV
Gag p27+ cells by day 5 PI) was considerably less effective compared
with blocking of more resistant clones. These data suggest that the
highly susceptible clones express alternative receptor(s) in addition
to CCR5, andmore resistant clones express this putative receptor(s) at
lower densities. In linewith this, Riddick et al. (2010) recently showed
that a mutated CCR5 gene encoding a truncated molecule that is not
expressed on the cell surface does not protect sooty mangabeys from
infection with the “R5-tropic” SIVsmm virus in vivo. This, together
with our data, support previous studies (Forte et al., 2003) suggesting
that other surface molecules may also serve as co-receptors for SIV.
SIV Env has been shown to mediate target cell entry in cell-to-cell
fusion assays via interaction with chemokine receptor-like orphan
receptors such as CXCR6 (STRL33/Bonzo) and GPR15 (BOB) (Edinger
et al., 1998; Lauren et al., 2006; Pohlmann et al., 1999b). In contrast to
CCR5 regulation, we observed stable-to-slightly elevated surface
expression of CXCR6 by primary macaque CD4+ T-cells following
CD3 mAb stimulation, but its role in our model could not be directly
tested due to lack of suitable reagents. More studies are therefore
needed to more clearly deﬁne the possible role of CXCR6 and other as
of yet unknown receptors in mediating SIV entry into primary
macaque CD4+ cells.
Our data ﬁt a model where a very low threshold level of surface
CCR5 expression is required and sufﬁcient for efﬁcient SIVmac239
infection of macaque CD4+ T-cells, while low levels of infection can
occur through an alternate entry pathway also in the absence of CCR5.
Because CD4+ T-cells that are CCR5low following CD3mAb stimulation
or RNAi transduction express surface CCR5 at levels above this
hypothetical threshold, they are still highly susceptible to SIV. Thus,
attempts to prevent SIVmac239 infection by RNAi or other methods
that markedly reduce but fail to completely abrogate CCR5 expression
may not be effective, and direct silencing at the gene level using
reagents such as zinc-ﬁnger nucleases targeted to CCR5 may be more
successful (Perez et al., 2008).
Statistical analysis
Differences between geometric mean ﬂuorescent intensities
(GMFI) of surface CCR5 expression 24–48 h compared to 1 week
post CD3 mAb stimulation, and those of surface CD4 and CCR5
expression by SIV Gag p27+ compared to SIV Gag p27− cells on day 5
PI were analyzed using the paired Students t test. Comparison of CCR5
mRNA copies by different clones at resting and after CD3 mAb
stimulation were also performed using the paired Students t test. A
Spearman rank order correlation analysis was performed to assess any
correlation between the GMFI of surface CCR5 expression at time of
infection and SIV Gag p27 expression on day 5 PI. A p value≤0.05 wasconsidered statistically signiﬁcant. All tests were performed using the
software STATA 10.0 (StataCorp LP, College Station, TX, USA).
Materials and methods
Generation of primary rhesus macaque CD4+ T-cell clones
CD4+ T-cell clones were generated from PBMC isolated from three
naïve (96C114, DBGR and DBWL2) and ﬁve SIV DNA vaccinated
(AZ09, AZ15, C0102, DBN2 and FB1) (Minang et al., 2010) Indian
Rhesus macaques, Macaca mulatta. Both male and female animals
were included in the study and ranged in age between 4 and 14 years.
The CD4+ T-cell clones were maintained using bi-weekly stimulation
with antihuman-CD3 monoclonal antibodies (mAb) (30 ng/mL; clone
SP34-2; BD Biosciences, San Diego, CA, USA) and irradiated human
PBMC and a human Epstein–Barr virus transformed B-cell line (TM B-
LCL; kindly provided by Drs. S.R. Riddell and P. D. Greenberg, FHCRC,
Seattle, WA) as feeder cells as described (Minang et al., 2008). Feeder
cells were irradiated in a Mark I Cs137 γ-irradiator (Shepherd &
Associates, San Fernando, CA) at 6000 and 12,500 rad for PBMC and
TM B-LCL, respectively.
All CD4+ T-cell clones from the vaccinated animals were screened
for reactivity to SIV by assessing IFN-γ responses to vaccine antigens
using autologous PBMC pulsed with SIV Gag, Pol and Accessory (Acc)
peptide pools as described (Minang et al., 2010). Animal care was
according to the guidelines of the Committee on the Care and Use of
Laboratory Animals of the Institute of Laboratory Animal Resources,
National Research Council, and the Health and Human Services
guidelines “Guide for the Care and Use of Laboratory Animals”
(National Research Council, 1996, National Academy Press, Washing-
ton, D.C.), under an Institutional Animal Care and Use Committee
approved protocol.
Retroviral vectors expressing rhesus macaque CCR5 shRNA
MicroRNA-30-adapted CCR5 small hairpin RNA (miR-shRNA) were
designed by using the Cold Spring Harbor Laboratory web RNAi design
tool at http://katahdin.cshl.org/siRNA/RNAi.cgi?type=shRNA for
Macaca mulatta mRNA CCR5 target sequence (GenBank accession
number U73739). miR-shRNA oligonucleotide cassettes were inserted
into the retroviral vector MSCV-LTRmiR30-PIG (LMP) (Open Biosys-
tems, Huntsville, AL) (Dickins et al., 2005) according to the manufac-
turer's recommendations. The resulting miR-shRNA-expressing
constructs (LMP-miR-shRNA) were veriﬁed by sequencing.
To generate retroviral vector stocks, GP2-293 packaging cells
(Clontech, Mountain View, CA) were co-transfected with LMP-miR-
shRNA plasmid DNAs and vesicular stomatitis virus envelope G
glycoprotein (VSV-G)-expressing construct using TransIt®-293 trans-
fection reagent (Mirus Bio, Madison, WI). Forty-eight hours post
transfection, supernatants were harvested and retroviral vector
particles concentrated by centrifugation at 50,000×g as described
(Kutner et al., 2009) and resuspended in PBS to produce vector stocks.
Retroviral transduction of rhesus macaque CD4+ T-cells
Activated proliferating macaque CD4+ T-cells were transduced
with LMP-miR-shRNA retroviral vectors using RetroNectin transduc-
tion technique (Hanenberg et al., 1996) according to the manufac-
turer's recommendations. Brieﬂy, a 12-well cell culture plate was
coated with RetroNectin® reagent (TaKaRA Bio USA, Madison, WI)
and washed with PBS. To bind retroviral particles to the retronectin,
retroviral vector stocks were added and the plate was centrifuged at
2000×g (32 °C) for 2 h. The wells were washedwith PBS. The CD4+ T-
cells were resuspended in cell culture medium (RPMI 1640 supple-
mented with 10% fetal bovine serum, penicillin/streptomycin
[100 units/mL] and IL-2 [100 IU/mL]) and plated at 5×105 cells per
139J.T. Minang et al. / Virology 409 (2011) 132–140well. The plate was centrifuged at 500×g (32 °C) for 2 h and the cells
cultured for an additional 48 h at 37 °C. Transductants were identiﬁed
and sorted by ﬂow cytometry using a BD FACS Aria (BD Biosciences)
based on GFP ﬂuorescence. The cells were stained with ﬂourochrome-
conjugated anti-CCR5 mAb and CCR5 surface expression analyzed by
ﬂow cytometry (see section on ﬂow cytometric “Quantitation of SIV
Gag p27 expression”).
Virus stocks
Cell-free virus stocks used in this study were derived from the
molecular clone spxﬂ SIVmac239 (gift of Dr. Ronald Desrosiers, New
England Primate Research Center) (Genbank accession no. M33262.1)
(Kestler et al., 1990). Virus stocks were produced as previously
described (Minang et al., 2009).
SIV infection of primary rhesus macaque CD4+ T-cells
Polyclonal or clonal populations of PBMC-derived primary rhesus
macaque CD4+ T-cells were infected 24–48 h or 1 week after activation
with CD3 mAb. Cells were infected by incubating with aliquots of virus
stock for 2–3 h using the Viromag magnetofection reagents and
procedures according to manufacturer's recommendation (OzBios-
ciences, Marseille, France). Virus concentration and cell numbers were
as described (Minang et al., 2009). Virus-exposed CD4+ T-cells were
washed twice with PBS to remove residual non-incorporated viral
material and put in culture at a ﬁnal volume of 2 mL/well in 24-well
tissue culture plates. For CCR5 blocking experiments, CD4+ T-cell
clones were pretreated with 10 μM CCR5 antagonist maraviroc (AIDS
Research and Reference Program, Division of AIDS, NIAID) prior to virus
exposure and the drug added to the cell cultures every 2–3 days until
harvest and analyses. Initial titration experiments revealed that drug
concentrations above 10 μM did not convey any increased blocking
activity (data not shown).
Quantitation of SIV Gag p27 expression
The frequency of productively infected cells as a percentage of
target cell population was determined by staining for intracellular SIV
Gag expression using a FITC-conjugated SIV Gag p27 mAb (Clone 55-
2F12; NIH AIDS Research and Reference Reagent Program), in concert
with staining for other surface markers at deﬁned time points post
infection (PI). All mAbs were obtained from BD Biosciences (San Jose,
CA, USA) unless otherwise indicated. The following mAbs conjugated
to the indicated ﬂuorochromes were used for surface staining: CD4-
FITC or -PerCP-Cy5.5 (clone L200), CCR5-PE or -APC (clone 3A9),
CXCR6 (STRL33/Bonzo)-APC (clone 56811; R&D Systems), GPR15
(BOB) (Clone 367902; R&D Systems) in combination with rat anti-
mouse IgG2a+b PE (clone X57). The surface and intracellular staining
procedure and subsequent analyses by ﬂow cytometry was as
previously described (Minang et al., 2009).
Analysis of cell-associated viral DNA
To assess the levels of cell-associated viral DNA, cell samples were
harvested 9, 24, 48 and 96 h after infection of the CD4+ T-cells and
cell-associated viral DNA copies quantiﬁed by gag gene-speciﬁc real
time PCR as previously described (Cline et al., 2005).
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2010.10.005.
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